New drug cocktail takes on Hard-to-Treat leukemia
NCT ID NCT05396859
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a combination of two drugs—entrectinib and ASTX727—in people with a specific, hard-to-treat form of acute myeloid leukemia (AML) that has returned or not responded to treatment. The study aims to find the safest dose and watch for side effects in 13 adults whose leukemia has a TP53 gene mutation. The hope is that the two drugs together can kill more cancer cells than either alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
entrectinib and ASTX727 (decitabine and cedazuridine)
What this could lead to
If it works, this could point toward a new treatment option for people with a hard-to-treat form of AML that has come back or not responded to therapy.
What could go wrong
This is a very early, small Phase I trial with only 13 participants, focused on safety and dosing. It is too soon to know if the combination will be effective, and there may be significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States